Key Takeaways:
- Johnson & Johnson (JNJ, Financial) offers a solid dividend yield of 3.2%, appealing to income-focused investors.
- Analysts forecast a potential upside of 8.74% with an average target price of $170.64.
- The stock is rated "Outperform" with a compelling GF Value estimate suggesting further growth potential.
In the volatile landscape of today's economy, Johnson & Johnson (JNJ) distinguishes itself as a beacon of stability, underpinned by a noteworthy dividend yield of 3.2%. With a diverse portfolio spanning medical technologies and pharmaceuticals including leading names like Stelara and Carvykti, it remains a robust pick for those with a cautious investment strategy.
Wall Street Analysts' Projections
From a survey of 24 financial analysts, the average one-year price target for Johnson & Johnson (JNJ, Financial) is projected at $170.64. This spectrum ranges from a high estimate of $185.00 down to a low of $150.00. With the current stock price at $156.92, this indicates a potential upside of 8.74%. Investors can delve deeper into predictive analytics on the Johnson & Johnson (JNJ) Forecast page.
Furthermore, the consensus from 26 brokerage firms places Johnson & Johnson (JNJ, Financial) at an average brokerage recommendation of 2.3, which equates to an "Outperform" rating. Notably, this rating system spans from 1, representing a "Strong Buy," to 5, which suggests a "Sell."
According to GuruFocus, the estimated GF Value for Johnson & Johnson (JNJ, Financial) stands at $188.92 in the coming year. This valuation hints at a more significant upside of 20.39% from its current price. The GF Value metric integrates historical trading multiples, prior business expansion, and future business performance forecasts to gauge the stock's fair market value. Further comprehensive details are available on the Johnson & Johnson (JNJ) Summary page.
